PET-based molecular imaging in personalized oncology: Potential of the assessment of therapeutic outcome

Future Oncology

Volumn 11, Issue 7, 2015, Pages 1083-1091

  Dimitrakopoulou Strauss, Antonia ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

molecular imaging; oncology; personalized medicine; PET; therapy monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; IMATINIB; RITUXIMAB; TRACER;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; HODGKIN DISEASE; HUMAN; LYMPHOMA; METASTASIS; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; ONCOLOGY; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; STANDARDIZATION; TREATMENT RESPONSE; NEOPLASMS; PROCEDURES; SCINTISCANNING; TREATMENT OUTCOME;

HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PRECISION MEDICINE; TREATMENT OUTCOME;

EID: 84925711186     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.28     Document Type: Review

References (51)

1. Strauss LG, Conti PS. The applications of PET in clinical oncology. J. Nucl. Med. 32, 623-648 (1991).
2. Kostakoglu L, Cheson BD. State-of-the-art research on "lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response". Front. Oncol. 3, 212 (2013).
3. Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 9, 475-481 (2006).
4. Zinzani PL, Rigacci L, Stefoni V et al. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur. J. Nucl. Med. Mol. Imaging 39, 4-12 (2012).
5. Hutchings M, Kostakoglu L, Zaucha JM et al. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin Lymphoma. J. Clin. Oncol. 32, 2705-2711 (2014).
6. Engert A, Haverkamp H, Kobe C et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD 15 trial): A randomized, open-label, Phase 3 non-inferiority trial. Lancet 379, 1791-1799 (2012).
7. Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk. Lymphoma 50, 1761-1764 (2009).
8. Le Roux PY, Gastinne T, Le Gouill S et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of international harmonization project (IHP), Gallamini and London criteria. Eur. J. Nucl. Med. Mol. Imaging 38, 1064-1071 (2011).
9. Rutkowski P, Gronchi A, Hohenberger P et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): The EORTC STBSG experience. Ann. Surg. Oncol. 20, 2937-2943 (2013).
10. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G et al. Impact of dynamic 18F-FDG PET on early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: A feasibility study. J. Nucl. Med. 51, 551-558 (2010).
11. Jones RP, Malik HZ, Fenwick SW, Poston GJ. Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur. J. Surg. Oncol. 39, 807-811 (2013).
12. Shao YC, Chang YY, Lin JK et al. Noeadjuvant chemotherapy can improve outcome of colorectal cancer patients with unresectable metastasis. Int. J. Colorectal Dis. 28, 1359-1365 (2013).
13. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16, 2672-2685 (1998).
14. Humbert O, Berriolo-Riedinger A, Riedinger JM et al. Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann. Oncol. 23, 2572-2577 (2012).
15. Koolen BB, Pengel KE, Wesseling J et al. Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Med. Mol. Imaging 41, 32-40 (2014).
16. Groheux D, Giacchetti S, Hatt M et al. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Br. J. Cancer 109, 1157-1164 (2013).
17. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur. J. Nucl. Med. Mol. Imaging 37, 1481-1489 (2010).
18. Dimitrakopoulou-Strauss A, Strauss LG, Burger C et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J. Nucl. Med. 45, 1480-1487 (2004).
19. Eigentler TK, Schlaak M, Hassel JC et al. Effectiveness and tolerability of ipilimumab. Experiences from 198 patients included in a named-patient program in various dailypractice settings and multiple institutions. J. Immunother. 37, 374-381 (2014).
20. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
21. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2016 (2011).
22. Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET-CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur. J. Nucl. Med. Mol. Imaging doi:10.1007/s00259-014-2944-y (2014) (Epub ahead of print).
23. Le Cesne A, Blay JY, Reichardt P, Joenssu H. Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression. Oncologist 18, 1192-1199 (2013).
24. Nastoupil LJ, Sinha R, Byrtek M et al. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 120, 1830-1837 (2014).
25. Guliani F, De Vita F, Colucci G, Pisconti S. Maintenance therapy in colon cancer. Cancer Treat. Rev. 36(Suppl. 3), S42-S45 (2010).
26. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, 122S-150S (2009).
27. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
28. Lacombe D, Tejpar S, Salgado R et al. European perspective for effective cancer drug development. Nat. Rev. Clin. Oncol. 11, 492-498 (2014).
29. Verweij J, de Jonge M, Eskens F, Sleijfer S. Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical drug desing. Mol. Oncol. 6, 196-203 (2012).
30. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R et al. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-(F-18)-fluoro-D-glucose positron emission tomography: A feasibility study. Mol. Imaging Biol. 9, 308-317 (2007).
31. Dimitrakopoulou-Strauss A, Hohenberger P, Pan L, Kasper B, Roumia S, Strauss LG. Dynamic PET (dPET) with FDG in patients with unresectable aggressive fibromatosis: regression-based parametric images and correlation to the FDG kinetics based on a two-tissue compartmen mode. Clin. Nucl. Med. 37, 336-344 (2012).
32. Kratochwil C, Combs SE, Leotta K et al. Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol. 16, 434-440 (2014).
33. Nanni C, Zanoni L, Fanti S. Nuclear medicine in urological cancers: what is new? Future Oncol. 10, 2061-2072 (2014).
34. Van Kruchten M, de Vries EG, Brown M et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 14, 465-475 (2013).
35. Dimitrakopoulou-Strauss A, Strauss LG. The role of 18F-FLT in cancer imaging: does it really reflect proliferation? Eur. J. Nucl. Med. Mol. Imaging 35, 523-526 (2008).
36. Kawai N, Lin W, Cao WD et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1a and VEGF in newly diagnosed and recurrent malignant gliomas. Eur. J. Nucl. Med. Mol. Imaging 41, 1870-1878 (2014).
37. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. Nucl. Med. 46, 763-769 (2005).
38. Koukouraki S, Strauss LG, Georgoulias V et al. Comparison of the pharmacokinetics of 68Ga-DOTATOC and (18F)FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33, 1115-1122 (2006).
39. Vinjamuri S, Gilbert TM, Banks M et al. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: Assessment of response, survival and toxicity. Br. J. Cancer 108, 1440-1448 (2013).
40. Kratochwil C, Stefanova M, Mavriopoulou E et al. SUV of 68Ga-DOTATOC PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol. Imaging Biol. doi:10.1007/s11307-014-0795-3 (2014) (Epub ahead of print).
41. Eder M, Schafer M, Bauder-Wust, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug. Chem. 23, 688-697 (2012).
42. Eder M, Neels O, Müller M et al. Novel preclinical and radiopharmaceutical aspects of 68Ga-PSMA-HBED-CC: A new PET tracer for imaging of prostate cancer. Pharmaceuticals 7, 779-796 (2014).
43. Afshar-Oromieh A, Haberkorn U, Schlemmer HP et al. Comparison of PET/CT and PET/ MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur. J. Nucl. Med. Mol. Imaging 41, 887-897 (2014).
44. Zechmann CM, Afshar-Oromieh A, Armor T et al. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer treatment. Eur. J. Nucl. Med. Mol. Imaging 41, 1280-1292 (2014).
45. Behe M, Alt K, Deininger F et al. In vivo testing of 177Lu-labelled anti-PSMA antibody as a a new radioimmunotherapeutic agent against prostate cancer. In Vivo 25, 55-59 (2011).
46. Lütje S, Franssen GM, Sharkey RM et al. Anti-CEA antibody fragments labeled with 18F-AIF for PET imaging of CEA-expressing tumors. Bioconjug. Chem. 25, 335-341 (2014).
47. Sundaresan G, Yazaki PJ, Shively JE et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigenspecific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 44, 1962-1969 (2003).
48. Olafsen T, Betting D, Kenanova VE et al. Recombinant anti-CD20 antibody fragments for microPET imaging of B-cell lymphoma. J. Nucl. Med. 50, 1500-1508 (2009).
49. Tamura K, Kurihara H, Yonemori K et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J. Nucl. Med. 54, 1869-1875 (2013).
50. Gaykema SB, Brouwers AH, Lub-de Hooge MN et al. 89Zr-bevacizumab PET imaging in primary breast cancer. J. Nucl. Med. 54, 1014-1018 (2013).
51. Buetow KH. Bioinformatics in personalized cancer care. In: Genomic and Personalized Medicine. Ginsburg GF, Willard HF (Eds). Elsevier Inc. 789-797 (2013).